References
1. P Argani, et al. Clear cell sarcoma of the kidney: a review of 351
cases from the National Wilms Tumor Study Group Pathology Center. Am J
Surg Pathol 2000 Jan;24(1):4-18.
2. R. Furtwangler, et al. Clear Cell Sarcomas of the Kidney registered
on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP
2001 protocols: A report of the SIOP Renal Tumour Study Group. Eur J
Cancer 2013;49:3497-3506.
3. S. L. Gooskens, et al. Clear cell sarcoma of the kidney: A review.
Eur J Cancer 2012;48:2219-2226.
4. Nita L. Seibel, et al. Effect of Duration of Treatment on Treatment
Outcome for Patients With Clear-Cell Sarcoma of the Kidney: A Report
From the National Wilms’ Tumor Study Group. J Clin Oncol
2004;22(3):468-73.
5. Nita L. Seibel, et al. Impact of cyclophosphamide and etoposide on
outcome of clear cell sarcoma of the kidney treated on the National
Wilms Tumor Study‐5 (NWTS‐5). Pediatr Blood Cancer 2019;66(1):e27450.
6. S. L. Gooskens, et al. Treatment and outcome of patients with
relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP
study. Br J Cancer 2014;111:227-233.
7. Ueno-Yokohata H, et al. Consistent in-frame internal tandem
duplications of BCOR characterize clear cell sarcoma of the kidney. Nat
Genet 2015;47(8):861-3.
8. Angshumoy Roy, et al. Recurrent internal tandem duplications of BCOR
in clear cell sarcoma of the kidney. Nature Commun 2015;6:8891.
9. O’Meara E, et al. Characterization of the chromosomal translocation
t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol
2012;227(1):72-80.
10. André Fehr, et al. YWHAE-FAM22 gene fusion in clear cell sarcoma of
the kidney. J Pathol 2012;227:5-7.
11. Meng K Wong, et al. Clear cell sarcomas of the kidney are
characterised by BCOR gene abnormalities, including exon 15 internal
tandem duplications and BCOR–CCNB3 gene fusion. Histopathology
2018;72:320-329.
12. Masahiro Sekiguchi, et al. Integrated multiomics analysis of
hepatoblastoma unravels its heterogeneity and provides novel druggable
targets. NPJ Precis Oncol. 2020;4:20.
13. Dang HX, et al. ClonEvol: clonal ordering and visualization in
cancer sequencing. Ann Oncol 2017;28(12):3076-3082.
14. Shunsuke Kimura, et al. NOTCH 1 pathway activating mutations and
clonal evolution in pediatric T‐cell acute lymphoblastic leukemia.
Cancer Sci 2019;110:784-794.
15. Vlad C, et al. Treatment of recurrent clear cell sarcoma of the
kidney with brain metastasis. Pediatr Blood Cancer 2008;50(2):246-9.
16. Mossner M, et al. Mutational hierarchies in myelodysplastic
syndromes dynamically adapt and evolve upon therapy response and
failure. Blood 2016;128(9):1246-59.
17. Hiroyuki Nishiyama, et al. Negative regulation of G1/S transition by
the candidate bladder tumour suppressor gene DBCCR1. Oncogene
2001;20:2956-2964.
18. A Lopez-Beltran, et al. Loss of heterozygosity at 9q32–33 (DBC1
locus) in primary non-invasive papillary urothelial neoplasm of low
malignant potential and low-grade urothelial carcinoma of the bladder
and their associated normal urothelium. J Pathol 2008;215:263-272.
19. Eric J Gratias, et al. Gain of 1q is Associated with Inferior
Event-Free and Overall Survival in Favorable Histology Wilms Tumor: A
Report from the Children’s Oncology Group. Cancer 2013;119:3887-3894.
20. H Kuniyasu, et al. Frequent loss of heterozygosity of the long arm
of chromosome 7 is closely associated with progression of human gastric
carcinomas. Int J Cancer 1994;59:59-600.
21. Poetsch M, et al. Loss of heterozygosity at 15q21.3 correlates with
occurrence of metastases in head and neck cancer. Mod Pathol
2006;19(11):1462-9.
22. Rhiem K, et al. Chromosomal region 15q21.1 is a frequent target of
allelic imbalance in advanced breast carcinomas. Int J Cancer
2003;106(1):74-7.
23. Evert Jan Van Limbergen, et al. FLT1 kinase is a mediator of
radioresistance and survival in head and neck squamous cell carcinoma.
Acta Oncol 2014;53:637-645.
24. Bin-Zhi Qian, et al. FLT1 signaling in metastasis-associated
macrophages activates an inflammatory signature that promotes breast
cancer metastasis. J Exp Med 2015;212:1433-1448.
25. Vainchenker W, et al. JAK/STAT signaling in hematological
malignancies. Oncogene 2013;32:2601-13.
26. Chloe James, et al. A unique clonal JAK2 mutation leading to
constitutive signaling causes polycythaemia vera. Nature 2005;434:
1144-8.
27. Alexandra Wolf, et al. JAK2-V617F-induced MAPK activity is regulated
by PI3K and acts synergistically with PI3K on the proliferation of
JAK2-V617F-positive cells. JAKSTAT 2013;2;e24574.
28. Li F, et al. YAP1-Mediated CDK6 Activation Confers Radiation
Resistance in Esophageal Cancer – Rationale for the Combination of YAP1
and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res
2019;25(7):2264-2277.
29. Kurimchak A M, et al. Intrinsic Resistance to MEK Inhibition through
BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian
Cancer. Mol Cancer Res 2019;17(8):1721-1734.
30. Sophie M. Stief, et al. Loss of KDM6A confers drug resistance in
acute myeloid leukemia. Leukemia 2020;34:50-62.